MX2024004558A - Tratamiento de la uveitis con inhibidores de la aminopeptidasa 1 de reticulo endoplasmatico (erap1). - Google Patents
Tratamiento de la uveitis con inhibidores de la aminopeptidasa 1 de reticulo endoplasmatico (erap1).Info
- Publication number
- MX2024004558A MX2024004558A MX2024004558A MX2024004558A MX2024004558A MX 2024004558 A MX2024004558 A MX 2024004558A MX 2024004558 A MX2024004558 A MX 2024004558A MX 2024004558 A MX2024004558 A MX 2024004558A MX 2024004558 A MX2024004558 A MX 2024004558A
- Authority
- MX
- Mexico
- Prior art keywords
- uveitis
- erap1
- inhibitors
- treatment
- endoplasmic reticulum
- Prior art date
Links
- 206010046851 Uveitis Diseases 0.000 title abstract 3
- 101710168245 Endoplasmic reticulum aminopeptidase 1 Proteins 0.000 title 2
- 102100021598 Endoplasmic reticulum aminopeptidase 1 Human genes 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Analytical Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163255597P | 2021-10-14 | 2021-10-14 | |
| US202263328008P | 2022-04-06 | 2022-04-06 | |
| PCT/US2022/078037 WO2023064850A1 (en) | 2021-10-14 | 2022-10-13 | Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004558A true MX2024004558A (es) | 2024-07-10 |
Family
ID=84332068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004558A MX2024004558A (es) | 2021-10-14 | 2022-10-13 | Tratamiento de la uveitis con inhibidores de la aminopeptidasa 1 de reticulo endoplasmatico (erap1). |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12157891B2 (https=) |
| EP (1) | EP4416286A1 (https=) |
| JP (1) | JP2024536491A (https=) |
| MX (1) | MX2024004558A (https=) |
| WO (1) | WO2023064850A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8968731B2 (en) * | 2009-10-09 | 2015-03-03 | Csl Limited | Treatment of uveitis |
| US20130315933A1 (en) * | 2010-10-06 | 2013-11-28 | Christoph Renner | Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy |
| TWI619729B (zh) * | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| WO2014155278A2 (en) * | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| EP4058429A1 (en) | 2019-11-14 | 2022-09-21 | Grey Wolf Therapeutics Limited | Erap1 modulators |
| AU2021316196B2 (en) | 2020-07-25 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Modulation of endoplasmic reticulum aminopeptidase 2 (ERAP2)-mediated immune response |
-
2022
- 2022-10-13 US US18/046,291 patent/US12157891B2/en active Active
- 2022-10-13 JP JP2024522207A patent/JP2024536491A/ja active Pending
- 2022-10-13 WO PCT/US2022/078037 patent/WO2023064850A1/en not_active Ceased
- 2022-10-13 MX MX2024004558A patent/MX2024004558A/es unknown
- 2022-10-13 EP EP22802441.0A patent/EP4416286A1/en active Pending
-
2024
- 2024-10-24 US US18/925,493 patent/US20250115918A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12157891B2 (en) | 2024-12-03 |
| WO2023064850A1 (en) | 2023-04-20 |
| US20250115918A1 (en) | 2025-04-10 |
| US20230250434A1 (en) | 2023-08-10 |
| EP4416286A1 (en) | 2024-08-21 |
| JP2024536491A (ja) | 2024-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49508B1 (fr) | Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques | |
| MX2023007587A (es) | Tratamiento de enfermedades hepaticas con inhibidores de efectores b tipo dffa que inducen la muerte celular (cideb). | |
| EA200700333A1 (ru) | Терапевтические применения ингибиторов rtp801 | |
| CY1109295T1 (el) | Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον | |
| BRPI0309665B8 (pt) | método para analisar uma preparação de alfagalactosidase a | |
| CY1115745T1 (el) | Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου | |
| EP1639141A4 (en) | METHOD FOR THE TREATMENT OF LENTIVIRUS INFECTIONS | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA202191133A1 (ru) | Сигнатуры интерферона типа i и способы их применения | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| WO2022015573A8 (en) | Sars-cov-2 antigen-binding proteins and uses thereof | |
| BR112021017550A2 (pt) | Métodos de tratamento da amiloidose al | |
| BR112022013646A2 (pt) | Método de tratamento de esplenomegalia | |
| EA201791401A1 (ru) | СПОСОБ ТЕРАПЕВТИЧЕСКОГО ЛЕЧЕНИЯ СИНДРОМА РАЗДРАЖЁННОГО КИШЕЧНИКА С ПРЕОБЛАДАНИЕМ ДИАРЕИ С ПРИМЕНЕНИЕМ Bacillus coagulans SBC37-01, MTCC 5856 | |
| EA202092540A1 (ru) | Комбинации для лечения рака | |
| MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. | |
| MX2022014254A (es) | Anticuerpos anti-hemojuvelina (hjv) para tratar mielofibrosis. | |
| MX2024004558A (es) | Tratamiento de la uveitis con inhibidores de la aminopeptidasa 1 de reticulo endoplasmatico (erap1). | |
| EA202192961A1 (ru) | Ребамипид для применения в профилактике и/или лечении синуклеинопатий | |
| EA202192176A1 (ru) | Нарушения, опосредованные интерфероном i типа | |
| EA202190862A1 (ru) | Способы лечения | |
| NO20055448L (no) | Kombinasjon av et analeptisk modafinil og en antidepressiv forbindelse for behandling av depresjon | |
| MX2024007900A (es) | Tratamiento de enfermedades renales con inhibidores de la angiopoyetina tipo 3 (angptl3). | |
| EA202090439A1 (ru) | Способы и материалы для оценки и лечения рака |